Archives of Neuroscience

Published by: Kowsar

Deficits in Striatal Dopamine and Hippocampal Serotonin Following Induction of Anxiety/Depressive-Like Behaviors by Bisphenol A

Meng Jia 1 and Julian Pittman 1 , *
Authors Information
1 Department of Biological and Environmental Sciences, Troy University, Troy, AL 36083, USA
Article information
  • Archives of Neuroscience: January 01, 2015, 2 (1); e18555
  • Published Online: January 1, 2015
  • Article Type: Research Article
  • Received: February 26, 2014
  • Revised: March 17, 2014
  • Accepted: March 20, 2014
  • DOI: 10.5812/archneurosci.18555

To Cite: Jia M, Pittman J. Deficits in Striatal Dopamine and Hippocampal Serotonin Following Induction of Anxiety/Depressive-Like Behaviors by Bisphenol A, Arch Neurosci. 2015 ; 2(1):e18555. doi: 10.5812/archneurosci.18555.

Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Meireles J, Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol. 2012; 3: 88[DOI][PubMed]
  • 2. Ohno Y. Mapping the progress of Alzheimer's and Parkinson's disease. 2002; : 423-8[DOI]
  • 3. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004; 363(9423): 1783-93[DOI][PubMed]
  • 4. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996; 8(4): 383-92[PubMed]
  • 5. Ishibashi T, Ohno Y. Antiparkinsonian actions of a selective 5-HT 1A agonist, tandospirone, in rats. Biogenic Amines, 18. 2004; 3(6): 329-38[DOI]
  • 6. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, et al. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 2006; 1112(1): 126-33[DOI][PubMed]
  • 7. Mignon L, Wolf WA. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl). 2002; 163(1): 85-94[DOI][PubMed]
  • 8. Ohno Y. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Cent Nerv Syst Agents Med Chem. 2010; 10(2): 148-57[PubMed]
  • 9. Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, et al. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(5): 1302-7[DOI][PubMed]
  • 10. Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, et al. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res. 2009; 87(7): 1645-58[DOI][PubMed]
  • 11. Cheshire PA, Williams DR. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci. 2012; 19(3): 343-8[DOI][PubMed]
  • 12. Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, et al. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl). 2008; 199(1): 99-108[DOI][PubMed]
  • 13. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res. 2005; 52(2): 185-94[DOI][PubMed]
  • 14. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci. 1998; 861: 288-9[PubMed]
  • 15. Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, et al. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord. 2012; 27(6): 735-42[DOI][PubMed]
  • 16. Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, et al. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry. 1997; 154(4): 490-6[PubMed]
  • 17. Willner P, D'Aquila PS, Coventry T, Brain P. Loss of social status: preliminary evaluation of a novel animal model of depression. J Psychopharmacol. 1995; 9(3): 207-13[DOI][PubMed]
  • 18. Roy A, Pickar D, Linnoila M, Doran AR, Ninan P, Paul SM. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res. 1985; 15(4): 281-92[PubMed]
  • 19. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW. Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res. 1997; 769(1): 135-40[PubMed]
  • 20. Van den Belt K, Verheyen R, Witters H. Comparison of vitellogenin responses in zebrafish and rainbow trout following exposure to environmental estrogens. Ecotoxicol Environ Saf. 2003; 56(2): 271-81[PubMed]
  • 21. Villeneuve DL, Garcia-Reyero N, Escalon BL, Jensen KM, Cavallin JE, Makynen EA, et al. Ecotoxicogenomics to support ecological risk assessment: a case study with bisphenol A in fish. Environ Sci Technol. 2012; 46(1): 51-9[DOI][PubMed]
  • 22. vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol. 2007; 24(2): 131-8[DOI][PubMed]
  • 23. Levin ED, Bencan Z, Cerutti DT. Anxiolytic effects of nicotine in zebrafish. Physiol Behav. 2007; 90(1): 54-8[DOI][PubMed]
  • 24. Tracker. 2013;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments